Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 234

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease

Open access
Gladwin, Mark T., Shelhamer, James H., Ognibene, Frederick P., Pease‐Fye, Margaret E., Nichols, James S., Link, Beth, Patel, Daksesh B., Jankowski, Marcin A., Pannell, Lewis K., Schechter, Alan N., Rodgers, Griffin P.·2002·British Journal of Haematology

Abstract

Summary. Hydroxyurea therapy reduces the rates of vaso‐occlusive crisis in patients with sickle cell anaemia and recent data suggest that hydroxyurea treatment can generate nitric oxide (NO). Nitric oxide has been proposed as a novel therapy for sickle cell disease via a number of pathways. We therefore sought to determine whether hydroxyurea has NO donor properties in patients with sickle cell anaemia and explore potential mechanisms by which NO production could be therapeutic. Venous blood was collected from 19 fasting sickle cell anaemia patients, on chronic hydroxyurea therapy, at baseline and 2 and 4 h after a single morning dose of hydroxyurea, as well as 10 patients not taking hydroxyurea. The plasma and red cell NO reaction products nitrate, nitrite and nitrosylated‐ haemoglobin were measured using ozone‐based chemiluminescent assays (using vanadium, KI and I 3– reductants respectively). Consistent with NO release from hydroxyurea, baseline levels of total nitrosylated haemoglobin increased from 300 nmol/l to 500 nmol/l (P = 0·01). Plasma nitrate and nitrite levels also significantly increased with peak levels observed at 2 h. Glutathionyl–haemoglobin levels were unchanged, while plasma secretory vascular cellular adhesion molecule‐1 levels were reduced in patients taking hydroxyurea (419 ± 40 ng/ml) compared with control patients with sickle cell anaemia (653 ± 55 ng/ml; P = 0·003), and were inversely correlated with fetal haemoglobin levels (r = −0·72; P = 0·002). These results demonstrate that hydroxyurea therapy is associated with the intravascular and intraerythrocytic generation of NO. The role of NO in the induction of fetal haemoglobin and possible synergy between NO donor therapy and classic cytostatic and differentiating medications should be explored.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2141.2002.03274.x

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 234

Metadata

Authors
Gladwin, M. T., Shelhamer, J. H., Ognibene, F. P., Pease‐Fye, M. E., Nichols, J. S., Link, B., Patel, D. B., Jankowski, M. A., Pannell, L. K., Schechter, A. N., & Rodgers, G. P.
Venue
British Journal of Haematology
Publisher
Wiley
Published
2002-02
Volume
116
Issue
2
Pages
436-444
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W2013392029
Cited by
234
References
9
FWCI
5.89
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. https://app.cochat.ai/papers/10.1046/j.1365-2141.2002.03274.x
The paper
Gladwin, M. T., Shelhamer, J. H., Ognibene, F. P., Pease‐Fye, M. E., Nichols, J. S., Link, B., Patel, D. B., Jankowski, M. A., Pannell, L. K., Schechter, A. N., & Rodgers, G. P. (2002). Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. British Journal of Haematology. https://doi.org/10.1046/j.1365-2141.2002.03274.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.